Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 55, Issue 2, 2010, Pages 239-247

  Nagatoshi, Yoshihisa ^a   Matsuzaki, Akinobu ^b   Suminoe, Aiko ^b   Inada, Hiroko ^c   Ueda, Kouichiro ^c   Kawakami, Kiyoshi ^d   Yanai, Fumio ^e   Nakayama, Hideki ^f   Moritake, Hiroshi ^g   Itonaga, Nobuyoshi ^h   Hotta, Noriko ⁱ   Fujita, Kyoko ^j   Hidaka, Yasufumi ^k   Yamanaka, Takeharu ^a   Kawano, Yoshifumi ^a,l   Okamura, Jun ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kagoshima City Hospital   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g UNIVERSITY OF MIYAZAKI   (Japan)

^h OITA PREFECTURAL HOSPITAL   (Japan)

ⁱ YAMAGUCHI UNIVERSITY   (Japan)

^j Tokuyama Central Hospital   (Japan)

^k KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^l KAGOSHIMA UNIVERSITY   (Japan)

more..

Author keywords

6 MP MTX with VCR and DEX; LSA2l2 type; Maintenance therapy; Pediatric acute lymphoblastic leukemia

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ENOCITABINE; ETOPOSIDE; FOLINATE CALCIUM; MERCAPTOPURINE; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADRENAL INSUFFICIENCY; ARTICLE; BRAIN DISEASE; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOPHENOTYPING; INTERSTITIAL PNEUMONIA; LEUKOCYTE COUNT; LIPOMATOSIS; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DRUG-INDUCED LIVER INJURY; HUMANS; INFANT; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 77955102218     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22528     Document Type: Article

References (38)

1. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
2. Aricò M, Valsecchi M, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 2008;26:283-289.
3. Moghrabi A, Levy D, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-0 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
4. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730-2741.
5. Conter V, Valsecchi M, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: A multicentre randomised trial. Lancet 2007;369:123-131.
6. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18:1508-1516. (Pubitemid 30205397)
7. Matsuzaki A, Ishii E, Okamura J, et al. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols:Areport from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol 1996;26:10-19.
8. Ishii E, Eguchi H, Matsuzaki A, et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: Impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol 2001;37:10-19.
9. Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1990;75:166-173. (Pubitemid 20031505)
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
12. Greenwood M. A report on the natural duration of cancer. London: Her Majesty's Stationery Office; 1926.
13. Cox D. Regression models and life tables. J R Stat Soc 1972;34:187-220.
14. Pui C, Evans W. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-615.
15. Schmiegelow K, Heyman M, Kristinsson J, et al. Oral methotrexate/6- mercaptopurine may be superior to a multidrug LSA2L2 maintenance therapy for higher risk childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol 2009;31:385-392.
16. Chauvenet A, Martin P, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201. Blood 2007;110:1105-1111.
17. Matloub Y, Lindemulder S, Gaynon P, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: Results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006;108:1165-1173.
18. Manabe A, Tsuchida M, Hanada R, et al. Delay of the diagnostic lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia who undergo routine corticosteroid testing: Tokyo Children's Cancer Study Group Study L89-12. J Clin Oncol 2001;19:3182-3187.
19. Schultz K, Pullen D, Sather H, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-935.
20. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771-782.
21. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
22. Hijiya N, Hudson M, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. J Am Med Assoc 2007;297:1207-1215.
23. Chow EJ, Friedman DL, Yasui Y, et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia:Areport from the Childhood Cancer Survivor Study. J Pediatr 2007;150:370-375.
24. Waber D, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 2007;25:4914-4921.
25. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743.
26. Smith M, Rubinstein L, Anderson J, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577. (Pubitemid 29075244)
27. Le Deley M, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 2003;21:1074-1081.
28. Neglia J, Friedman D, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-629. (Pubitemid 32409629)
29. Hill F, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004;124:33-46. (Pubitemid 38021621)
30. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-2275.
31. Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: Long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 2003;21:1790-1797.
32. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009;10:957-966.
33. Mitchell C, Richards S, Kinsey S, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745. (Pubitemid 40904523)
34. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coliasparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group Phase 3 trial. Blood 2002;99:2734-2739.
35. Lauer S, Shuster J, Mahoney W, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial. Leukemia 2001;15:1038-1045.
36. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-1671.
37. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: Areport from the Children's Cancer Group. Blood 2003;101:3809-3817.
38. Lange B, Bostrom B, Cherlow J, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2002;99:825-833. (Pubitemid 34525542)